OREANDA-NEWS. July 22, 2015. Singapore Exchange (SGX) today welcomed iX Biopharma Ltd (iX Biopharma) to Catalist under the stock code “42C”.

iX Biopharma is a Singapore incorporated pharmaceutical company focused on the development and commercialisation of products for the treatment of acute pain and erectile dysfunction.  It also provides chemical analysis services for pharmaceutical products. iX Biopharma manages and undertakes its research and development in Singapore and Australia.

Professor Paul Edward Rolan, Director of Drug Development, iX Biopharma said, “This listing is significant as it brings us a step closer towards our goal of commercialising our products currently under development.  We are also heartened by the confidence that our shareholders have in the Company.  We look forward to completing our clinical trials in a timely manner, and promise to work hard to create good value for them.”

Mohamed Nasser Ismail, Head of SME Development & Listing, SGX, said, “We are pleased to welcome iX Biopharma to SGX. With an increasing focus on healthcare and improved therapies in the region, iX Biopharma is well-placed to benefit from the resultant growth in its industry. We look forward to supporting the company on its growth journey.”

The listing of iX Biopharma brings the total number of healthcare companies on SGX to 31 with a combined market capitalisation of over S\\$38 billion. Following iX Biopharma’s IPO, the Catalist board will have 160 companies with a total market capitalisation of about S\\$10 billion.

iX Biopharma opened at \\$0.495 today, 8% up from the offer price.